A detailed history of Wells Fargo & Company transactions in Trevi Therapeutics, Inc. stock. As of the latest transaction made, Wells Fargo & Company holds 23,488 shares of TRVI stock, worth $95,126. This represents 0.0% of its overall portfolio holdings.

Number of Shares
23,488
Previous 23,478 0.04%
Holding current value
$95,126
Previous $69,000 13.04%
% of portfolio
0.0%
Previous 0.0%

Shares

16 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 13, 2024

BUY
$2.58 - $3.51 $25 - $35
10 Added 0.04%
23,488 $78,000
Q2 2024

Aug 13, 2024

BUY
$2.44 - $3.36 $16,199 - $22,307
6,639 Added 39.43%
23,478 $69,000
Q1 2024

May 10, 2024

BUY
$1.3 - $3.7 $5,040 - $14,344
3,877 Added 29.91%
16,839 $58,000
Q4 2023

Feb 09, 2024

BUY
$1.06 - $2.05 $2,848 - $5,508
2,687 Added 26.15%
12,962 $17,000
Q3 2023

Nov 13, 2023

SELL
$2.11 - $2.47 $11,735 - $13,738
-5,562 Reduced 35.12%
10,275 $22,000
Q2 2023

Aug 15, 2023

BUY
$1.8 - $3.44 $28,029 - $53,567
15,572 Added 5876.23%
15,837 $37,000
Q1 2023

May 12, 2023

BUY
$1.69 - $2.97 $6 - $11
4 Added 1.53%
265 $0
Q4 2022

Feb 13, 2023

BUY
$1.61 - $2.42 $196 - $295
122 Added 87.77%
261 $0
Q3 2022

Nov 14, 2022

SELL
$1.54 - $4.28 $41 - $115
-27 Reduced 16.27%
139 $0
Q2 2022

Aug 12, 2022

BUY
$1.8 - $3.39 $167 - $315
93 Added 127.4%
166 $0
Q4 2021

Feb 14, 2022

BUY
$0.68 - $1.5 $18 - $40
27 Added 58.7%
73 $0
Q3 2021

Nov 15, 2021

BUY
$1.29 - $2.18 $16 - $28
13 Added 39.39%
46 $0
Q2 2021

Aug 16, 2021

BUY
$2.0 - $2.76 $18 - $24
9 Added 37.5%
33 $0
Q1 2021

May 13, 2021

BUY
$2.36 - $3.55 $4 - $7
2 Added 9.09%
24 $0
Q3 2020

Nov 05, 2020

SELL
$3.5 - $7.62 $49 - $106
-14 Reduced 38.89%
22 $0
Q1 2020

May 14, 2020

BUY
$1.71 - $5.87 $61 - $211
36 New
36 $0

Others Institutions Holding TRVI

About Trevi Therapeutics, Inc.


  • Ticker TRVI
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 58,322,500
  • Market Cap $236M
  • Description
  • Trevi Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of Haduvio to treat serious neurologically mediated conditions. The company is developing Haduvio, an oral extended-release formulation of nalbuphine, which is in phase IIb/III clinical trial for the treatment of chronic pruritu...
More about TRVI
Track This Portfolio

Track Wells Fargo & Company Portfolio

Follow Wells Fargo & Company and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Wells Fargo & Company, based on Form 13F filings with the SEC.

News

Stay updated on Wells Fargo & Company with notifications on news.